ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2650

Cognitive Impairment in SLE and Non-Criterion Anti-Phospholipid Antibodies

Michael Luggen1, Gaurav Gulati2, Rohan Willis3 and Emilio B. Gonzalez3, 1Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, 2Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, 3Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies, Cognitive dysfunction and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose: The pathogenesis of cognitive impairment (CI) in patients with SLE is unknown. Anti-phospholipid antibodies (APL) have been implicated in some studies, but not in others. The APL which have been evaluated have variably included anti-cardiolipin (ACL) antibodies, lupus anticoagulant (LAC), and antibodies to beta-2 glycoprotein I (β2GPI).  Few studies have examined all of the above and none has examined other APL (so-called non-criterion APL). We evaluated the association of CI with a broad spectrum of both criterion and non-criterion APL. 

Methods:  Subjects meeting the revised criteria for classification of SLE were recruited from 3 different patient populations. Cognitive function was assessed with the ANAM (Automated Neuropsychologic Assessment Metrics), a validated computer- based assessment tool which measures multiple cognitive domains.  The TTS (total throughput score= number of correct responses/time) was used as the primary outcome measure. It was summed over 8 separate domains. Demographic, clinical, treatment, disease activity and damage information was obtained.  The following APL of all three isotypes were assessed by ELISA using standardized techniques:  ACL, anti-β2GPI, anti-phosphatidyl ethanolamine (aPE), anti-phosphatidyl choline (aPC), anti-phosphatidyl inositol (aPI), anti-phosphatidyl serine (aPS), anti-phosphatidyl glycerol (aPG), anti-phosphatidic acid (aPA). The data were analyzed by Fisher’s exact test, Wilcoxon rank sum test, and multiple linear regression.

 Results: Fifty-seven (57) patients were evaluated.  Clinical characteristics are shown in Table 1. Of the 57, 12 had definite CI (<1.5 SD below the mean of an age, sex, and race matched RA population). The two groups were significantly different with regard to age, ethnicity, and family income. There was no significant difference between groups with regard to the presence or absence of any APL, or any specific APL, criterion or non-criterion.  When titers of specific APL were compared with TTS, no significant correlations were found.  Using multiple linear regression and adjusting for age, ethnicity, income, opioid and hydroxychloroquine use, and simple reaction time, neither the presence nor the titer of any APL significantly decreased TTS. However, the presence of aPG (IgM) (b’= 0.352, p = .0007) and aPA (IgG) (b’=0.242,p=.02) appeared to increase TTS (model R2=.731, p<0.0001).

Conclusion:   In this cross-sectional study, neither criterion nor non-criterion APL of any isotype was associated with a significant decrease in cognitive performance as measured by the TTS of the ANAM.  Somewhat surprisingly,  aPG (IgM) and aPA (IgG) appeared to increase TTS, possibly reflecting protection against other pathogenic factors. Confirmation and further analysis of this finding is in progress.

 

 

 

 

                                                           


Disclosure:

M. Luggen,
None;

G. Gulati,
None;

R. Willis,

Louisville APL Diagnostics Inc,

5;

E. B. Gonzalez,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cognitive-impairment-in-sle-and-non-criterion-anti-phospholipid-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology